Covid 19 Research using Clinical Trials (Home Page)
HP:0002758: OsteoarthritisHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3051 | wedged insole Wiki | 0.50 |
| drug1683 | On-line exercise and education Wiki | 0.50 |
| drug801 | Dynamic 3D bone motion capture Wiki | 0.50 |
| drug1312 | LRX712 Wiki | 0.50 |
| drug1684 | On-site exercise and education Wiki | 0.50 |
| drug2282 | Software Messaging Wiki | 0.50 |
| drug1822 | Placebo Wiki | 0.03 |
Correlated MeSH Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D010003 | Osteoarthritis, NIH | 1.00 |
| D020370 | Osteoarthritis, Knee NIH | 0.58 |
| D015207 | Osteoarthritis, Hip NIH | 0.50 |
| D013315 | Stress, Psychological NIH | 0.11 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005086 | Knee osteoarthritis HPO | 0.58 |
| HP:0008843 | Hip osteoarthritis HPO | 0.50 |
There are 4 clinical trials
Clinical Trials
1 Improving the Detection, Classification and Treatment of Misaligned Arthritic Ankles
The Veteran population is prone to foot and ankle maladies from common injuries such as sprains, and diseases such as ankle osteoarthritis (cartilage damage). More specific to Veterans are prior service injuries of the foot and ankle, which historically account for nearly a quarter of injuries received. These injuries include bone fractures and ligament damage. Some of these injuries may lead to poor ankle joint alignment, which over time could lead to osteoarthritis due to abnormal wear on a day to day basis. The goal of this proposal is to use a novel technology - biplane fluoroscopy, to study the movement of ankles which are misaligned in subjects with ankle osteoarthritis. This proposal will also benefit current diagnostic methods with additional information. Last, this proposal will test the effectiveness of a conservative treatment (modified shoe insoles) to correct or reduce the misalignment in ankles. This proposal will create evidence about: the nature of ankle osteoarthritis, the accuracy of diagnosing alignment, and conservative treatment for patients with ankle OA.
NCT03440008 Ankle Osteoarthritis Other: Dynamic 3D bone motion capture Device: wedged insole MeSH:Osteoarthritis
HPO:Osteoarthritis
Primary Outcomes
Description: The 3D movement between the tibia and talus bones will be assessed using biplane fluoroscopy, for OA and control subjects during shod gait.
Measure: Tibio-talar kinematics during gait Time: 4 hour session
Description: The sensitivity to correctly diagnose dynamic misalignment by using static x-ray images, will be determined for the OA population.
Measure: Static ankle alignment sensitivity Time: 4 hour session
Description: The effect that wedged insoles have on varus / valgus misalignment will be assessed using dynamic 3D x-ray
Measure: Decrease in misalignment during gait using wedged insoles Time: 4 hour session
2 A Randomized, Placebo-controlled, Subject and Investigator Blinded Study Investigating the Safety, Tolerability and Preliminary Efficacy of 8-week Treatment With Intra-articular LRX712 to Regenerate Articular Cartilage in Patients With Mild/Moderate Knee Osteoarthritis
Primary Outcomes
Description: The 3D movement between the tibia and talus bones will be assessed using biplane fluoroscopy, for OA and control subjects during shod gait.
Measure: Tibio-talar kinematics during gait Time: 4 hour sessionDescription: The sensitivity to correctly diagnose dynamic misalignment by using static x-ray images, will be determined for the OA population.
Measure: Static ankle alignment sensitivity Time: 4 hour sessionDescription: The effect that wedged insoles have on varus / valgus misalignment will be assessed using dynamic 3D x-ray
Measure: Decrease in misalignment during gait using wedged insoles Time: 4 hour sessionThis study will explore the preliminary efficacy of multiple intra-articular injections of LRX712 by evaluating the ability of the drug to restore structural integrity of articular cartilage. Efficacy will be evaluated in the context of the systemic safety and local tolerability of the investigational drug.
NCT04097379 Osteoarthritis (OA) Drug: LRX712 Drug: Placebo MeSH:Osteoarthritis
HPO:Osteoarthritis
Primary Outcomes
Description: Efficacy of multiple intra-articular injections of LRX712 in regenerating cartilage as measured with 7T MRI
Measure: Changes in articular cartilage [23Na] content from baseline compared to placebo at week 28 Time: Baseline and Week 28
Secondary Outcomes
Description: Efficacy of multiple intra-articular injections of LRX712 measured with 7T MRI
Measure: Changes in articular cartilage [23Na] content from baseline compared to placebo at Week 16 and 52 Time: Baseline, Week 16 and 52
Description: Efficacy of multiple intra-articular injections of LRX712 measured with 7T MRI
Measure: Changes from baseline in cartilage morphometrics (volume and thickness) in the medial femoral condyle at Week 16, 28 and 52 Time: Baseline, Week 16, 28 and 52
Description: The observed time to reach max (Tmax) plasma concentration following drug administration
Measure: Time to Reach the Maximum Plasma Concentration (Tmax) Time: Pre-dose to 28 weeks
Description: The observed maximum (Cmax) plasma concentration following drug administration
Measure: Maximum Observed Plasma Concentration (Cmax) Time: Pre-dose to 28 weeks
Description: The observed minimum (Cmin) plasma concentration following drug administration
Measure: Minimum Observed Plasma Concentration (Cmin) Time: Pre-dose to 28 weeks
Description: The observed synovial concentration following drug administration
Measure: Concentration in synovial fluid Time: Day 1; week 4; week 8
3 Acceptance and Commitment Therapy Delivered by Automated Software Messaging
Primary Outcomes
Description: Efficacy of multiple intra-articular injections of LRX712 in regenerating cartilage as measured with 7T MRI
Measure: Changes in articular cartilage [23Na] content from baseline compared to placebo at week 28 Time: Baseline and Week 28Secondary Outcomes
Description: Efficacy of multiple intra-articular injections of LRX712 measured with 7T MRI
Measure: Changes in articular cartilage [23Na] content from baseline compared to placebo at Week 16 and 52 Time: Baseline, Week 16 and 52Description: Efficacy of multiple intra-articular injections of LRX712 measured with 7T MRI
Measure: Changes from baseline in cartilage morphometrics (volume and thickness) in the medial femoral condyle at Week 16, 28 and 52 Time: Baseline, Week 16, 28 and 52Description: The observed time to reach max (Tmax) plasma concentration following drug administration
Measure: Time to Reach the Maximum Plasma Concentration (Tmax) Time: Pre-dose to 28 weeksDescription: The observed maximum (Cmax) plasma concentration following drug administration
Measure: Maximum Observed Plasma Concentration (Cmax) Time: Pre-dose to 28 weeksDescription: The observed minimum (Cmin) plasma concentration following drug administration
Measure: Minimum Observed Plasma Concentration (Cmin) Time: Pre-dose to 28 weeksDescription: The observed synovial concentration following drug administration
Measure: Concentration in synovial fluid Time: Day 1; week 4; week 8This study aims to 1) observe the course of pain, 2) mental status, and 3) possible effect of a behavioral intervention delivered via an automated mobile phone messaging robot in patients were indicated and/or scheduled to undergo joint replacement but have been cancelled or delayed due to the COVID-19 crisis.
NCT04329897 Hip Osteoarthritis Knee Osteoarthritis Mental Stress Coronavirus Behavioral: Software Messaging MeSH:Osteoarthritis Osteoarthritis, Knee Osteoarthritis, Hip Stress, Psychological
HPO:Hip osteoarthritis Knee osteoarthritis Osteoarthritis
Primary Outcomes
Description: PROMIS Pain Intensity 3A short form is a 3 question survey measuring an individual's pain over the past 7 days. It utilizes a scale of 1 (no pain) to 5 (very severe pain) for all questions. The scores for the 3 questions are summed and then matched to a corresponding t-score for the instrument. The corresponding t-score is the final, reportable score and can range from 30.7 to 71.8 for the PROMIS Pain Intensity 3A instrument. Higher t-score values represent worse pain outcomes. More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.
Description: PROMIS Pain Intensity 1A short form is a 1 question survey measuring an individual's average pain over the past 7 days. It utilizes a scale of 0 (no pain) to 10 (worst imaginable pain). Higher values represent worse pain outcomes.
More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.
Description: The PROMIS Pain Interference 8A short form is an 8 question survey that measures how much pain has interfered in the respondent's life over the past 7 days. It utilizes a scale of 1 (not at all) to 5 (very much) for all questions.
The scores for all 8 questions are summed and then matched to a corresponding t-score for the instrument. The corresponding t-score is the final, reportable score and can range from 40.7 to 77.0 for the PROMIS Pain Interference 8A instrument. Higher t-score values represent worse pain interference outcomes.
More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.
Description: The PROMIS Emotional Distress-Anxiety 8A short form is an 8 statement survey that measures how much emotional distress, specifically due to anxiety, a respondent has experienced over the past 7 days. It utilizes a scale of 1 (never) to 5 (always) for all the statements. The scores for all 8 statements are summed and then matched to a corresponding t-score for the instrument. The corresponding t-score is the final, reportable score and can range from 37.1 to 83.1 for the PROMIS Emotional Distress-Anxiety 8A instrument. Higher t-score values represent worse anxiety caused emotional distress outcomes. More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.
4 On-line Neuromuscular Exercise and Education for Knee Osteoarthritis
Primary Outcomes
Description: PROMIS Pain Intensity 3A short form is a 3 question survey measuring an individual's pain over the past 7 days. It utilizes a scale of 1 (no pain) to 5 (very severe pain) for all questions. The scores for the 3 questions are summed and then matched to a corresponding t-score for the instrument. The corresponding t-score is the final, reportable score and can range from 30.7 to 71.8 for the PROMIS Pain Intensity 3A instrument. Higher t-score values represent worse pain outcomes. More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.Description: PROMIS Pain Intensity 1A short form is a 1 question survey measuring an individual's average pain over the past 7 days. It utilizes a scale of 0 (no pain) to 10 (worst imaginable pain). Higher values represent worse pain outcomes. More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.Description: The PROMIS Pain Interference 8A short form is an 8 question survey that measures how much pain has interfered in the respondent's life over the past 7 days. It utilizes a scale of 1 (not at all) to 5 (very much) for all questions. The scores for all 8 questions are summed and then matched to a corresponding t-score for the instrument. The corresponding t-score is the final, reportable score and can range from 40.7 to 77.0 for the PROMIS Pain Interference 8A instrument. Higher t-score values represent worse pain interference outcomes. More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.Description: The PROMIS Emotional Distress-Anxiety 8A short form is an 8 statement survey that measures how much emotional distress, specifically due to anxiety, a respondent has experienced over the past 7 days. It utilizes a scale of 1 (never) to 5 (always) for all the statements. The scores for all 8 statements are summed and then matched to a corresponding t-score for the instrument. The corresponding t-score is the final, reportable score and can range from 37.1 to 83.1 for the PROMIS Emotional Distress-Anxiety 8A instrument. Higher t-score values represent worse anxiety caused emotional distress outcomes. More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.Due to enforced social distancing as a direct consequence of the COVID-19 pandemic, many on-site health care services are unavailable. This study seeks to investigate the relative effectiveness of an alternative on-line delivery model of exercise and education compared to on-site delivery in patients with knee osteoarthritis.
NCT04437134 Knee Osteoarthritis Other: On-line exercise and education Other: On-site exercise and education MeSH:Osteoarthritis Osteoarthritis, Knee
HPO:Knee osteoarthritis Osteoarthritis
Primary Outcomes
Description: Summary score from the Knee injury and Osteoarthritis Outcome Score, short version (KOOS 12). The summary score is calculated as the average score from the KOOS 12 subscales pain, function and quality of life (QOL), ranging from 0 (worst) to 100 (best).
Measure: Knee impact summary Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Secondary Outcomes
Description: Fast-paced walking ability is recorded by the physiotherapists and evaluated using the 40-m fast-paced walk test.
Measure: Fast-paced walking ability Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months)
Description: Chair-stand ability is recorded by the physiotherapists and evaluated using the 30-s chair-stand test.
Measure: Chair-stand ability Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months)
Description: Patients self-report of function during daily life using the subscale function from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported function Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Description: Patients self-report of pain using the subscale pain from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported pain Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Description: Patients self-report of quality of life using the subscale quality of life from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported quality of life Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Description: Mean pain intensity during the last week in the most affected knee is evaluated on a 100 mm visual analogue scale (VAS) with terminal descriptors of 'no pain' (0 mm) and 'maximum pain' (100 mm).
Measure: Pain intensity Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Description: Patients self-report of time spent (frequency and duration) on structured physical activity and exercise.
Measure: Physical activity and exercise Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Other Outcomes
Description: Patients self-report of satisfaction with the GLA:D program.
Measure: Patient satisfaction Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Description: Patients self-reporting if, how and where they have continued exercising.
Measure: Continuation of exercise Time: Follow-up point: 12 months
Description: Patients self-report their current activity levels using the University of California, Los Angeles (UCLA) activity scale, ranging from 1 (inactive, dependent on others) to 10 (regular participation in high-impact sports).
Measure: Self-reported activity levels Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Description: Patients self-report of use of acquired skills and knowledge from the GLA:D program.
Measure: Usage of what was learned during GLA:D Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Description: Patients self-report of how they handle flare-ups in their knee OA symptoms.
Measure: Symptom management Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Description: Intake of painkillers is evaluated by the physiotherapist asking the patients about intake of any joint related medication. If taking painkillers, the patients are asked which type and whether or not they were taken because of their knee pain.
Measure: Intake of pain killers Time: Primary follow-up: Change from baseline to completion of GLA:D program (an average of three months).
Description: Patients self-report of sick leave due to knee symptoms.
Measure: Sick leave Time: Follow-up points: Baseline and 12 months
Description: Patients self-report of their health situation using EuroQol, 5 dimensions, 5 levels (EQ-5D-5L) score (-0.624 to 1; worst to best).
Measure: Health-related quality of life, index score Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Description: Patients self-report of their health situation using the EuroQol visual analogue scale (EQ VAS), ranging from 0-100 (worst to best).
Measure: Health-related quality of life, visual analogue scale Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Description: Patients self-report of current knee condition compared to before participation in GLA:D, scored on a 7-point likert scale (much worse to much better).
Measure: Global perceived effect Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months
Description: Patients self-report of pain during each exercise session, rated using a numeric pain rating scale (NPRS) 0-10, with zero representing no pain and 10 representing extreme pain.
Measure: Pain during exercise (only for on-line group) Time: Immediately prior to, and immediately after each exercise session
HPO Nodes
HP:0002758: Osteoarthritis
Genes 86
CCN6 COL9A3 TNFRSF11B CCN6 ZNF687 COMP PHEX MATN3 TRPV4 COL2A1 SMAD3 F9 TRPS1 UFSP2 TRAPPC2 COL1A1 MEFV COL5A1 AIP COMP SLC40A1 ATP7B TGFB3 COL9A1 ACAN MATN3 ASPN FBN1 COL2A1 LMNA MMP13 CANT1 COL2A1 PHEX COL2A1 EXT2 COL2A1 COL2A1 GNAS AEBP1 COL2A1 CLCN7 COL5A2 FGFR3 ACAN F8 SCARB2 ANKH COL2A1 COL9A1 COL11A2 GDF5 GHR HLA-B COL11A2 COMP EXT1 TRPV4 COL9A3 TRAPPC2 ANKH COL11A1 COL5A1 UFSP2 ZMPSTE24 COL11A2 GBA COL1A1 LMX1B ACAN GPR101 COMP COL2A1 FRZB SLC26A2 COL9A2 KIF7 HPGD KIF22 SMAD3 CLCN7 COL3A1 MATN3 COL9A2 HGD MMP13 Protein Mutations 1
Q28D SNP 0
Primary Outcomes
Description: Summary score from the Knee injury and Osteoarthritis Outcome Score, short version (KOOS 12). The summary score is calculated as the average score from the KOOS 12 subscales pain, function and quality of life (QOL), ranging from 0 (worst) to 100 (best).
Measure: Knee impact summary Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsSecondary Outcomes
Description: Fast-paced walking ability is recorded by the physiotherapists and evaluated using the 40-m fast-paced walk test.
Measure: Fast-paced walking ability Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months)Description: Chair-stand ability is recorded by the physiotherapists and evaluated using the 30-s chair-stand test.
Measure: Chair-stand ability Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months)Description: Patients self-report of function during daily life using the subscale function from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported function Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of pain using the subscale pain from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported pain Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of quality of life using the subscale quality of life from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported quality of life Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Mean pain intensity during the last week in the most affected knee is evaluated on a 100 mm visual analogue scale (VAS) with terminal descriptors of 'no pain' (0 mm) and 'maximum pain' (100 mm).
Measure: Pain intensity Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of time spent (frequency and duration) on structured physical activity and exercise.
Measure: Physical activity and exercise Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsOther Outcomes
Description: Patients self-report of satisfaction with the GLA:D program.
Measure: Patient satisfaction Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-reporting if, how and where they have continued exercising.
Measure: Continuation of exercise Time: Follow-up point: 12 monthsDescription: Patients self-report their current activity levels using the University of California, Los Angeles (UCLA) activity scale, ranging from 1 (inactive, dependent on others) to 10 (regular participation in high-impact sports).
Measure: Self-reported activity levels Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of use of acquired skills and knowledge from the GLA:D program.
Measure: Usage of what was learned during GLA:D Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of how they handle flare-ups in their knee OA symptoms.
Measure: Symptom management Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Intake of painkillers is evaluated by the physiotherapist asking the patients about intake of any joint related medication. If taking painkillers, the patients are asked which type and whether or not they were taken because of their knee pain.
Measure: Intake of pain killers Time: Primary follow-up: Change from baseline to completion of GLA:D program (an average of three months).Description: Patients self-report of sick leave due to knee symptoms.
Measure: Sick leave Time: Follow-up points: Baseline and 12 monthsDescription: Patients self-report of their health situation using EuroQol, 5 dimensions, 5 levels (EQ-5D-5L) score (-0.624 to 1; worst to best).
Measure: Health-related quality of life, index score Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of their health situation using the EuroQol visual analogue scale (EQ VAS), ranging from 0-100 (worst to best).
Measure: Health-related quality of life, visual analogue scale Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of current knee condition compared to before participation in GLA:D, scored on a 7-point likert scale (much worse to much better).
Measure: Global perceived effect Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of pain during each exercise session, rated using a numeric pain rating scale (NPRS) 0-10, with zero representing no pain and 10 representing extreme pain.
Measure: Pain during exercise (only for on-line group) Time: Immediately prior to, and immediately after each exercise session